Mitozolomide (INN) is an antineoplastic. It is an imidazotetrazine derivative.Development of mitozolomide was discontinued during Phase II clinical trials after it was found to cause severe and unpredictable bone marrow suppression. Temozolomide which has been in clinical use since 1999 is a less toxic analogue of mitozolomide.
This page contains content from the copyrighted Wikipedia article "Mitozolomide"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
